Phase II study evaluating the efficacy and safety of cetuximab associated with the protocol FOLFIRINOX [oxaliplatin + irinotecan + folinic acid + fluorouracil] (LV [leucovorin] 5FU [5-fluorouracil] simplified combined with irinotecan and oxaliplatin) in the first line treatment in patients with metastatic colorectal cancer expressing EGFR [epidermal growth factor receptor] or not.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 18 Feb 2021 Biomarkers information updated
- 13 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 13 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.